Testing cevostamab for lupus with kidney involvement
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called cevostamab for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. Some participants also have lupus nephritis, which means the disease is affecting their kidneys. The drug may help by targeting a specific part of the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed SLE diagnosis for at least 6 months before the study starts
- If you have lupus kidney disease, it must be confirmed by a kidney biopsy within 9 months of screening
- Active lupus disease confirmed by blood tests (SLEDAI-2K score)
- Previous lupus treatments haven't worked well enough or caused side effects you couldn't tolerate
- Not pregnant, breastfeeding, or planning to become pregnant during the study
- No recent or current serious infections, TB, or certain other immune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.